Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Advanced Technologies and Featured Challenges in Vaccine Research and Development
- Vaccinesworld 2017

Session/Tracks

With a great pleasure we welcome you to the official website of “21st World Congress andExhibition on Vaccines, Vaccination & Immunization” which is going tobe held during November 09-10,2017 in Vienna, Austria. Vaccines world 2017 will create a forum to improve knowledge translation to identify, discuss and troubleshoot the current Vaccine and Immunologyrelated issues across a range of disciplines and tracks under the Conference theme Advanced Technologies and Featured Challenges in Vaccine Research and Development


 Track 1: Novel Vaccines - Research and Development

Vaccine research&development has been slowly developed from the small pox human vaccine to human vaccines for rabies, tetanus, typhoid, yellow fever, influenza, chicken pox,hepatitis A, malaria, ebola and dengue fever as the timelinefrom 18th to 21st century.  It is an activity that focuses on avariety of technological initiatives, which enhance & promote improvedlatest system and practices for vaccine usage and safety. Vaccine development is a long, complexprocess, often lasting 10-15 years and involving a combination of public andprivate involvement. So we must review all the failures to learn in order toovercome the current challenges in the vaccine development bystandardized the procedures and regulations accordingly. This will help toimprove the immunization of humanpopulation.



 Track2: Vaccination for Viral Diseases

Viraldiseases are contagious and rapidly spread from person to person, when a virusenters the body. It begins to multiply in the blood stream. Vaccines are using against someviral diseases such as chickenpox,flu(influenza), HIV/AIDS, human papilloma virus(HPV), rubella, Shingles, hepatitis, meningitis, pneumonia. Recently, anewtwo-dose herpes zoster vaccine called HZ/su was administered for the olderpeople, which is safe and reduces the risk for shingles. And also reduce thepost herpetic neuralgiaby nearly 90% in people aged 70 years and older. After all this year andresearchers are engaged in an outbreak race to eradicate Zika, a disease that links tosevere birth defects all around theworld.


 Track3: Human papilloma virus Infection

HPV is the viral transmittingdiseases through skin to skin contacts. According to the Centers for Disease Control and Prevention (CDC),HPV is the most common sexually transmitted infection that affects both men andwomen. HPV symptoms are genitalwarts and itching. HPV in woman causecervical cancer and warts in the sexual organs. Hpv test for thisinfections are pap test, DNA test and acetic(vinegar) acid solution test.Three vaccines are approved bythe FDA to prevent HPV infection:Gardasil, Gardasil 9 and Cervarix.



Vaccination schedules are also approved by FDAto use in the males and females in certain age to improvetheir immunization against hpv infection

 Track4: Cancer Immunotherapy

Researchersare trying to develop vaccines to fight againstcancer for past decades, but this has proven to be harder than was firstthought. The cancer cells natural defense suppresses the immune system of the host and grows rapidlywithin their population. So the researchers are using the knowledge gained inrecent years to improve how they develop cancer vaccines. Hereby, their deliver vaccines along with other substances (calledadjuvants) that help boost up the body’s immune response, which might help the vaccines work better. Treatment cancer vaccines are given to the cancer patient afterthe chemotherapy to fight against the cancer cells.After chemotherapy, the cells will have poor immuneresponse. So this vaccine will act as thebarrier for invaders. All the cancer vaccines are still in the clinical level due tothe complex human immune systems. Cancer vaccine will be injected under the skin offenlyto activate the melanoma antigen.


 Track5: Vaccination for bacterial Diseases

Immunization schedule on the bacterial vaccinesare done around the world from the infant to adulthood to protect against somebacterial diseases with respective vaccine such as pneumoccal vaccine, tuberculosis vaccine, typhoid vaccine, chickenpox vaccine, yellow fever vaccine and several other bacterialvaccine. Recently in US, the immunization of two rodentspecies with new live-attenuated mutants of Yersinia pestis CO92 inducesprotection for long-term humoral and cell-mediated immunity against pneumonicplague. In every hospitals and online website we can find the vaccination chart and dose-level according to theepidemiology of the disease in the country with FDA approved.


 Track6: Infants/Children Vaccines

Immunization schedules are very important for theinfant/children ages between 0-6 years to protect against 14 diseases formbirth. These vaccines will improve the immune system againstthese diseases. During the birth, the immune system of the babies will be inthe developing stage. So the vaccine flushot will work well and start to produce theantibody for the 14 diseases periodically. It is currently recommended that allchildren receive vaccination against allinfectious diseases unless the child has special circumstances, such as acompromised immune system or neurological disorders.Without vaccines, epidemics of many preventable diseases could return,resulting in increased -and unnecessary - illness, disability, and death amongchildren. Recording of low levels of vaccine-preventable childhooddiseases in the United States does not mean these have disappeared. So it isimportant to vaccinate children,especiallyinfants and young children to receive recommended vaccine on time to improvisetheir immunisation.

Diseases

Trade-name of Vaccine

Diphtheria

DTaP, Tdap, DT, and Td

Tetanus

Pertussis

Hepatitis B

Vaqta, Twinrix,

Engerix-B, Recombivax HB

Polio

Kinrix, Pediarix, Pentacel

Meningococcal disease

MCV4, Menveo,

MPSV4, Menactra

Pneumococcal disease

Pneumococcal vaccine

Rotavirus

RotaTeq, Rotarix, Boostrix

Measles

Fluvirin, Ixiaro, ProQuad

Mumps

M-M-R II, ProQuad,

Menomune, Menactra

Rubella

Varicella (Chickenpox)

Influenza

Seqirus, trivalent (IIV3)


 Track7: Human Vaccines - Infectious & Non Infectious Diseases

Humanvaccines are used againstinfectious diseases to increase the immunization rate of the hostorganism and helps in eradicating the disease from the population. The National Health and Medical ResearchCouncil (NHMRC) is the major funding body in Australia for thevaccine research and development. Shingles vaccine used in adultto increase the immune response to get rid of painful skin rash. They publishedmany immunization schedules aboutpreventing infectious diseases in the infants and adults. DNA vaccines are usedto treat the non-infectious diseases against the allergy and cancer. DNAvaccines are optimized with modification in the antigen or tagged with adjuvants to improve thedelivery system. These allergy DNA vaccine alter the unwantedimmune response to fight the allergy while cancer DNA vaccine overcome immunesuppression and initiate strong immune response.


 Track 8: Vaccination for Pregnancy

Vaccinating the mother before, during and after the pregnancy is notonly protects the mother, it will also protect the baby’s health. Mother’simmunity is the first line of defense for the babies. Pregnant mothers shouldnot take live vaccine,such as Hepatitis B vaccine, poliovaccine, rabies vaccine and rota virusvaccine;because there's a slight chance these will harm the unborn baby. Somevaccines are made from dead viruses, such as the flu shot and toxoid vaccines aresafe,such as the tetanus/diphtheria/pertussis (Tdap) shot. The vaccine alsodepends on some dependent factors such as your age, lifestyle, medicalconditions, such as asthma ordiabetes& allergic conditions, locations of travel, and previousvaccinations. During pregnancy Tdap is recommended, preferably between 27 and36 weeks gestation, to protect baby from whooping cough.
 Track9: Vaccination for older/aged people

Aswe get aged, our immune systems become less effective to protect us from infectious and non-infectious disease. This meansthat we become more prone to catching infections and once we catch an infectionwe will take longer time to recover. Also, there is the chance to lose some ofour immunity to that disease which we were vaccinated against in childhood. Sotaking vaccine will help to improve the immunization of the body. Omitting vaccination leads to severe illnesses, long-termsuffering & death from preventable infections. Vaccine schedule also uploaded in the website of Centers for Diseases Control and Prevention(CDC).

Austrian biotech company AFFiRiS developed the vaccine for Parkinson’s diseases in the clinical level bytargeting the protein called alpha-synuclein to overcome the movement and memorydisorder in the older people


 Track10: Veterinary Vaccines

Veterinaryvaccine administered to animals to protectthemselves from the infectious diseases and also to protect the humans.Veterinary vaccine will improve the health of companionanimals, which leads to increase production of livestock in a cost-effectivemanner and prevent disease/infection transmission from animal-to-human fromboth domestic and wildlife animals. Several vaccine types can be distinguished among the 2ndgeneration of veterinary vaccines, depending upon whether they are live orinactivated, usage of the specific rabies virus strain & the characteristics ofthe cell substrate chosen for viral replication. Third generation of liveveterinary rabies vaccine has been developed usingrecombinant DNA technology in recent times. Depending upon the expressionsystem these vaccines are used either parentally or orally. Oral rabies vaccine is widely used in foxes in Europe and inraccoons in the USA. Veterinary biologics are regulated by the USDA Centre for Veterinary Biologics. The globalanimal vaccines market is poised to reach USD 7.68 Billion by 2021 from USD5.81 Billion in 2016, at a CAGR of 5.8% from 2016 to 2021.


 Track11: Plant-based vaccines

Plant-based vaccines are recombinant protein subunitvaccines. The challenges facing plant-based vaccine development include technical, regulatoryand economic aspects and public perception. In the technical challenges it isvery difficult to select a plant system where it grows under optimizedconditions to minimize the environmental risks. Ideally, the plant specieschoice used to produce the selected antigen should applicable for oral drug deliveryin an edible vaccine form. To date, the most advanced human vaccine projects have successfully completedphase I clinical trials, & animal vaccine projects have given promisingdata in early phase trials targeting the specific animal species.



 Track12: Clinical Trials in Animals Models

Clinicaltrials in the vaccine development takelong time as the commercial usage approval from FDA includes typical 5complicated steps. Recently, the WHO Initiative for Vaccine Research (IVR)collaborated with a wide range of partners to facilitate the development andfuture introduction of safe, effective and affordable zika vaccine. Now, it enters into the clinical trialphase I in humans. They are trying 5 different type of vaccine against zika.But the DNA based vaccine creates bliss amongthe types. DNA-based zika vaccine containskilled zika virus and not any infectious material. It is safer than thetraditional vaccine. The first will initially check the efficacy of thevaccine. But it doesn’t mean that it will come for the commercial vaccine usage.


 Track13: Side Effects of Vaccines

Vaccine is the best defense we have againstserious, preventable, and sometimes cause deadly contagious diseases. Vaccinesare some of the safest medical products available, but like other medicalproducts, there may be health risk. Accurate information about the value of vaccines as well as their possible side-effectshelps people to make informed decisions about vaccination. According to the Centers for Disease Control and Prevention (CDC)suggestion, the vaccine side effects areminor and it will go away within a few days. Side effects vary according tovaccine type, general side effects may include vomiting, Fatigue, headache,itching at injection site, dizziness, fever, mild skin rash. Anti-vaccineactivists are protesting against the vaccine, which cause autism in the birthbabies/infants.


 Track14: Vaccine Design-Immunoinformatics

Vaccine have long been used to fight againstinfectious disease; however the last decade has witnessed a revolution in theapproach to vaccine design and development. No longer isthere a need to rely on the laborious classical methods like attenuation orkilling the pathogenicity of microbes. Many sophisticated latest technologiescan be used for the rational identification of antigens to the synthesis ofcomplex engineered carrier proteins and much more. Immunoinformatics play the major role in vaccine design where everything is computer-aidedtechniques such as genomics, proteomics, and syntheticchemistry used to check the stability, strength and half-life of the vaccine bytargeting the specific gene through the comparative analysis.



Vaccine adjuvants - is an ingredient of a vaccinethat helps to create a stronger immunization in the patient’sbody.  In other words, adjuvant helps vaccine work better. Some vaccines prepared fromweakened or dead microbes will contain naturally occurring adjuvants and itwill help the body to produce a strong protective immunization. Vaccine delivery systems areengineered technologies for the targeted delivery and/or controlled release oftherapeutic agents to fight against the pathogens. Vaccination has long been used to improveimmunization and extend lives. The practice of vaccine delivery has changed dramatically in thelast few decades and even greater changes are anticipated in the near future.Synthetic vaccines, genomic analysis of disease and their vaccine response,structure-based antigen design, and nanotech delivery systems are just a few ofthe realizations of this effort. The tagged adjuvants/carrier also improvescellular and humoral immune responses againstthe antigen by their physio-chemical properties.
 Track16: Vaccination for Vector-borne Diseases

Vaccine may target blood-feedingdisease vectors, which includes mosquitoes and ticks, have the potential toprotect against many diseases that caused by vector-borne pathogens.Vector-borne diseases are the most complex of all infectious diseases toprevent & control. Vector- borne diseases, most of which are transmittedaround the home premises, were best controlled by a combination of vectorcontrol (use of public health insecticides on bed nets, or by spraying),medicines & vaccines.Vector borne diseases are Mosquito-borne diseases, Chikungunya, Dengue, Malaria, Yellow fever and Zika virus. Previous results saythat, successful vector-borne disease prevention result from management orelimination of vector populations.  Malaria was driven out in theUSA& most of Europe countries in this way. Where vector control has beenconsistently applied in the past, the results have been shown dramatic,especially with early efforts to control malaria by spraying inside thesurfaces of houses.

IndoorResidual Spraying (IRS) & long-lasting insecticide treated bed-nets havebeen very effective over the last 10 years & were widely regarded as one ofthe main contributors to more than 1 million lives saved. In contrast toexpenditure & effort on medicine, diagnostic & vaccine development, relatively little attentiongiven to vector control in the past.  The foresighted establishmentof IVCC in 2005, with a grant of Bill & Melinda Gates Foundation began theprocess of bringing Vector Control into the mainstream strategy for futureeradication of malaria& other vector-borne diseases.


 Track17: Vaccines for Neurodegenerative Disorder

Neurodegenerativediseases such as Alzheimer’s, Parkinson’sare among the leading causes of death in the western world. Most of theresearch institutes are working under the breakout of these diseases from thesociety by the vaccine technology. Recently, one of the AustrianResearch Centre AFFiRis invented vaccinesfor the Parkinson’s disease, whichis successful till theclinical trial levels.

About Conference

Allied Academies look forward to welcome all the participants across the globe to attend 21st World Congress and Exhibition on Vaccines, Vaccination & Immunization which is going to be held during November 09-10, 2017 in Vienna, Austria. The conference highlights the theme “Advanced Technologies and Featured Challenges in Vaccine Research and Developmentcovering all important aspects in Vaccines and their therapeutic methods.

Vaccines World 2017 conference features highly enlightening & interactive sessions to encourage the exchange of ideas across world in the field of vaccination and their therapeutic methods. The conference includes keynote talks from distinguished scientists, plenary sessions, business delegates, Poster Presentations, Young Researcher forum sessions, Symposiums, Workshop and Exhibitions.

We all know Infectious disease threat events (IDTEs) are increasing in frequency worldwide. We analyzed underlying drivers of 116 IDTEs detected in Europe during 2008–2013 by epidemic intelligence at the European Centre of Disease Prevention and Control. These infectious diseases are majorly transmitted through food-borne, waterborne, vector-borne and rodent-borne in all over the world. Especially in the border of European countries. Nearly half of the 27 Infectious diseases are within the vector-borne and rodent-borne category was caused by West Nile virus (WNV) infections. Four of these Infectious disease consisted of WNV cases in 4 different European countries and 1 large outbreak in south-eastern Europe with more-than 260 cases. Measles and mumps are still endemic in many European countries due to the poor vaccination coverage among country populations, migrants and vaccine hesitancy. So, Specific vaccination strategies are often necessary for these populations to improve the immunization of children and adults from infectious diseases, spread of infection due to crowded living conditions. And ensure the continuity of childhood immunization schedules

In order to accelerate the research in the field of Vaccination and Immunization Allied Academies organizes different conferences worldwide. American people focused on the industrial leaders and Medical professionals, Vaccine Research Development, Vaccine Business, Immunological Research, Vaccine Value Chain community, Immuno-informatics and Vaccine-Informatics. Vaccines Business tripled in value from $5 billion in 2000 to almost $24 billion in 2013, Vaccine Global market projected to raise up to $100 billion by 2025. UNICEY reached 1430 billion dollars in 2011 in the vaccines business as the global leader.

Why to attend???

21st World Congress and Exhibition on Vaccines, Vaccination and Immunization is a unique forum to bring together worldwide distinguished academics in the field of vaccinology and Immunology, Vaccine researchers, public health professionals, scientists, academic scientists, industry researchers, scholars to exchange about state of the art research and technologies. With members from around the world focused on learning about vaccines and vaccination effects; this is your best opportunity to reach the largest assemblage of participants from the vaccine and Immunology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in vaccines and its research are hallmarks of this conference. Aim of this conference is stimulate new ideas to develop the research of vaccine that will be beneficial across the spectrum of many infectious and non-infectious diseases.

Target Audience:

  • Vaccinology/Immunology Associations and Societies
  • CEOs and Directors from Vaccine research Centers
  • Business delegates from Industries 
  • Immunology Researcher and Scientists
  • Professors and Students from Academia
  • Manufacturing Medical Devices Companies
  • Vaccine manufacturing and production companies
  • pharmacists from hospitals

Conferenc Highlights:

 

Vaccines World 2017- Benefits



UNIQUE FEATURES of Vaccines World 2017

Keynote Talks | Exhibition | Workshops | Young Research Forum | Poster Presentation

  • Abstract will be published and it will be labelled with a Digital Object Identification Number (DOI) provided by Cross Ref.
  • Speaker and abstract pages will be created in Google on your name, so it will help you to get worldwide acknowledgment to your research profile.
  • The Career Guidance Workshops to the Doctorates, Post-Doctoral Fellows and Graduates.
  • Exhibition and B2B Meetings for Healthcare and Pharmaceutical Industries to exhibit their products to delegates and participants
  • Extra benefits and compliments for Exhibitor and Sponsors.

For more details - Contact: Stella Antony | Email: vaccinesworld@alliedconferences.org

Market Analysis

Vaccines World 2017 congress and exhibition features highly enlightening & interactive sessions to encourage the exchange of ideas across world in the field of vaccination and their therapeutic methods. The conference includes keynote talks from distinguished scientists, plenary sessions, business delegates, Poster Presentations, Young Researcher forum sessions, Symposiums, Workshop and Exhibitions.

Conferences, National symposiums and Workshops provide a dedicated forum for the advancement, execution and exchange of information about vaccine research and its allied areas.

Why Austria???

The global market for anti-counterfeiting packaging technologies is expected to increase from nearly$74.2 billion in 2015 to $135.6 billion in 2020, with a compound annual growth rate (CAGR) of 12.8% from 2015 to 2020. Influenza is a highly contagious viral disease. According to the report of World Health Organization, 15% of the world’s population get affected by this virus and cause a seasonal infection each year, leading to 250,000 to 500,000 deaths per year. Four Austrian companies including Baxter, Valneva, Marinomed Biotechnologie and Savira Pharmaceuticals are developing innovative ways to combat this debilitating viral infection and to prepare for possible future pandemics.

In Vienna, Hookipa Biotech is focusing on vaccines and pre-clinical and clinical development activities. In October 2011, Hookipa raised €7 million funds from internationally renowned venture capital investors. Now they are focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the VaxwaveTM technology and build a robust pre-clinical product pipeline.

In Austria, Valneva (one of the biologics manufacturing company) has a vaccine in clinical trials against Pseudomonas aeruginosa, which cause 10% of hospital-acquired severe bacterial infections. Probably by 2012 it is undergoing a Phase II/III trial. If it got huge success, then it will lead to another valuable weapon against killer infections in the hospital environment.


Conference Highlights:

Major Associations around the Globe for Vaccine and Immunology Research

  • European Federation for Immuno-genetics
  • European Society for Immunodeficiency
  • American Association of Immunologists
  • American Association of Veterinary Immunologists
  • Australasian Society for Immunology
  • British Society for Allergy and Clinical Immunology
  • British Society for Immunology
  • Society for Mucosal Immunology
  • International Society of Travel Medicine
  • The International Society of Neuro-immunology
  • The International Union of Immunological Societies
  • The Society for Travel Immunology
  • The Society for Leukocyte Biology
  • British Society for Immunology
  • European Federation of Immunological Societies
  • European Society of Gene Therapy
  • Federation of African Immunological Societies
  • Federation of American Societies for Experimental Biology
  • Federation of Clinical Immunology Societies
  • Immune Deficiency Foundation
  • Infectious Diseases Society of America

Companies Associated with Vaccines Research and Production

  • CareDx
  • Atara
  • Activartis
  • AFFiRiS
  • ·Hookipa Biotech Vienna,
  • s-TARget Therapeutics
  • Themis Bioscience
  • Valneva
  • Biotherapeutics
  • BenitecLimited
  • InterMune
  • Biotron Limited
  • BioDiem
  • Antisense Therapeutics Limited
  • Glaxo Smith Kline USA Pty Ltd
  • Bionomics
  • USAn Pharmaceutical Industries (API)
  • BioPharmica Limited

Hospitals Associated with Vaccine Research and development

  • Johns Hopkins Hospital Baltimore U.S
  • Chris Hani Baragwanath Hospital Johannesburg South Africa
  • Stanford Hospitals and Clinics U.S
  • Great Ormond Street Hospital London UK
  • University of Texas MD Anderson Cancer Centre Houston U.S
  • Harvard Medical School Boston U.S
  • Karolinska Hospital, Stockholm, Sweden
  • The Priory UK
  • Bumrungrad International Hospital Bangkok Thailand
  • Cedars-Sinai Medical Center Los Angeles U.S

 

Organizing Committee
OCM Member
Camille LOCHT
Research Director
French National Institute of Health and Medical Research
Paris, France
OCM Member
Guenther Staffler
CTO
AFFiRiS AG
Vienna, Austria
OCM Member
Geert C. Mudde
CSO and Managing Director
OncoQR ML GmbH
Vienna, Austria
OCM Member
Pierre A. MORGON
CEO, MRGN Advisors – Chairman
Virometix
Zurich, Switzerland
OCM Member
Tilahun Yilma
UC Davis School of Veterinary Medicine
San Francisco, USA
OCM Member
Louise Cosby
Professor, Centre for Infection and Immunity
Queen's University Belfast
London, United Kingdom
OCM Member
Martin Bachmann
Professor of Vaccinology, Department of Medicine
University of Oxford
London, United Kingdom
OCM Member
Eden, W. van (Willem)
Chair, Division of Immunology
Utrecht University
Amsterdam, Netherlands
OCM Member
Salim M. Adib
Professor
American University of Beirut
Beirut, Lebanon
OCM Member
Sonali Kochhar
CEO
Global Healthcare Consulting
New Delhi, India
OCM Member
Giulio Tarro
President
Foundation de Beaumont Bonelli for cancer research
Naples, Italy
Renowned Speakers

To Collaborate Scientific Professionals around the World

Conference Date November 9-10, 2017
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Venue
&
Hospitality

Fleming Hotel Wien-Westbahnhof
Neubaugürtel
26-28,1070 Vienna, Austria

Join The Discussion

Contact Desk

Registration Query

Stella Antony

vaccinesworld@alliedconferences.org

+1 800-858-2189

Abstract Submission

Stella Antony

vaccinesworld@alliedconferences.org

Special Issues
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
Media Partners
Collaborations
Copyright © 2017-2018 Allied Academies, All Rights Reserved.